Treatment of p16 (HPV)-Positive Squamous Cell Carcinoma of the Tonsil at Advanced Clinical Stage
Clinical Scenario
This protocol applies to squamous cell carcinoma of the tonsil (oropharynx) confirmed as p16 (HPV)-positive by immunohistochemistry, presenting at advanced clinical stage.
p16 / HPV-positive
T0–2, N1 (single node >3 cm or ≥2 ipsilateral nodes ≤6 cm)
T1–2, N2
T3, N0–2
T0–3, N3
T4, N0–3
Tumor Characterisation
HPV testing by p16 immunohistochemistry (IHC) is required for tonsil and oropharyngeal primary tumors. This protocol specifically covers cases confirmed p16-positive at the tonsil, base of tongue, posterior pharyngeal wall, or soft palate sites.
Treatment Approach
Management centres on combined-modality treatment of both the primary tumor and the neck. Concurrent radiation therapy with systemic therapy is the preferred strategy. Additional treatment paths — including surgical and induction-based approaches — exist for selected clinical situations. The complete regimen, sequencing criteria, and decision points are detailed in the full protocol.
References
- Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate
- Tumor human papillomavirus (HPV) testing by p16 IHC required
- p16 (HPV)-positive
- T0–2,N1 (single node >3 cm, or 2 or more ipsilateral nodes ≤6 cm), or T1–2,N2 or T3,N0–2
- T0–3,N3 or T4,N0–3
- Concurrent systemic therapy/RT (preferred)
- Resection of primary and ipsilateral or bilateral neck dissection
- Induction chemotherapy (category 3) followed by RT or systemic therapy/RT
- Clinical trials
- For those with clinical evidence of fixed or matted nodes or obvious extranodal extension, resection is not recommended and concurrent systemic therapy/RT is preferred.
View source ↗